Stacey Tannenbaum, PhD, FISoP is a scientist and leader in Model Informed Drug Development, serving as a consultant to the MIDD community to help individuals, teams, and organizations become even more impactful through the development of leadership, communication, and change management skills.
Previously, she was recently at Metrum Research Group as VP of Scientific Engagement, following 20 years of Pharmacometrics experience in industry from Novartis and Astellas, where she led the US Pharmacometrics group. Stacey earned a BSE in Biomedical Engineering (Duke University), a PhD in Pharmaceutical Sciences and Applied Mathematics (University of Arizona), and a post-doctoral fellowship at the Center for Drug Development Science (Georgetown University).
Stacey has had significant impact on the global Pharmacometrics community. She co-founded the International Society of Pharmacometrics (ISoP), serving as its first President and is an ISoP Fellow. Stacey co-founded the American Conference on Pharmacometrics (ACoP) and was conference chair for the first three events; she remains an active volunteer in both ISoP and ACoP. She is the Executive Committee chair for the World Conference on Pharmacometrics (WCoP), and is the chair of the Quantitative Pharmacology Network at the American Society of Clinical Pharmacology and Therapeutics (ASCPT). She served as a board member of the American Association of Pharmaceutical Scientists (AAPS), chaired the AAPS M&S Focus Group, and was the co-chair for the AAPS Forum for Connecting Predictive Modelers. Stacey also co-founded the networking group Modeling and Simulation Applications in Clinical Pharmacotherapy (MoSAiC).